Methods for treatment of and prophylaxis against inflammatory disorders
An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
1. A pharmaceutical composition, comprising:
a peptide consisting of the amino acid sequence of SEQ ID NO:4, wherein the amino acid sequence comprises at least one amino acid substitution or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the amino acid substitution is a nonconservative substitution.
3. The pharmaceutical composition of claim 1 , wherein the peptide is in an amount effective to substantially inhibit damage from inflammatory tissue injury.
4. The pharmaceutical composition of claim 1 , wherein the peptide does not substantially inhibit on more activities of a polymorphonuclear leukocyte (PMN) selected from the group consisting of chemotaxis, chemokine synthesis and secretion, cytokine synthesis and secretion, extracellular bacterial killing, intracellular bacterial killing, phagocytosis, and reactive oxygen species (ROS) generation.
5. The pharmaceutical composition of claim 1 , wherein the peptide is present in an amount effective to treat a patient having an inflammatory disorder selected from the group consisting of: acute respiratory distress syndrome (ARDS), bronchopulmonary dysplasia (BPD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, inflammation in cancer, inflammatory bowel disease (IBD), inflammatory lung disease (ILD), influenza-induced pneumonitis, necrotizing enterocolitis (NEC), neonatal chronic lung disease (CLD), periodontitis, pre-eclampsia, retinopathy of prematurity (ROP), sepsis, systemic inflammatory response syndrome (SIRS), thrombosis, transfusion-related acute lung injury (TRALI), vasculitis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Wegener's granulomatosis (WG).
6. The pharmaceutical composition of claim 1 , wherein the peptide is present in an amount effective to substantially inhibit NETosis or neutrophil extracellular trap (NET) formation.
7. The pharmaceutical composition of claim 6 , wherein the NETosis or NET formation is stimulated by at least one of a bacterium, a fungus, a parasite, or a virus.
8. The pharmaceutical composition of claim 7 , wherein the virus is selected from the group consisting of hemorrhagic fever virus, filovirus, Ebola virus, Marburg virus, arena virus, Lassa virus, hantavirus, flavivirus, dengue virus, yellow fever virus, or HIV-1.
9. The pharmaceutical composition of claim 7 , wherein the NETosis or NET formation is stimulated by at least one of the group selected from a Bacillus species, an Escherichia species, a Francisella species, a Staphylococcus species, a Streptococcus species, or a Yersinia species.
10. A method for treating neutrophil extracellular trap (NET) mediated inflammatory tissue damage in a patient, comprising:
administering to the patient an effective amount of a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO:4, wherein the amino acid sequence comprises at least one amino acid substitution or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier.
11. The method of claim 10 , wherein the pharmaceutical composition substantially inhibits NET-mediated inflammatory damage.
12. The method of claim 10 , wherein the peptide does not substantially inhibit one or more activities of a polymorphonuclear leukocyte (PMN) selected from the group consisting of chemotaxis, chemokine synthesis and secretion, cytokine synthesis and secretion, extracellular bacterial killing, intracellular bacterial killing, phagocytosis, and reactive oxygen species (ROS) generation.
13. The method of claim 10 , wherein the peptide is present in an amount effective to treat a patient having an inflammatory disorder selected from the group consisting of: acute respiratory distress syndrome (ARDS), bronchopulmonary dysplasia (BPD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, inflammation in cancer, inflammatory bowel disease (IBD), inflammatory lung disease (ILD), influenza-induced pneumonitis, necrotizing enterocolitis (NEC), neonatal chronic lung disease (CLD), periodontitis, pre-eclampsia, retinopathy of prematurity (ROP), sepsis, systemic inflammatory response syndrome (SIRS), thrombosis, transfusion-related acute lung injury (TRALI), vasculitis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Wegener's granulomatosis (WG).
14. The method of claim 10 , wherein the peptide is present in an amount effective to substantially inhibit NETosis or neutrophil extracellular trap (NET) formation.
15. The method of claim 14 , wherein the NETosis or NET formation is stimulated by at least one of a bacterium, a fungus, a parasite, or a virus.
16. The method of claim 15 , wherein the NETosis or NET formation is stimulated by a virus selected from at least one of a hemorrhagic fever virus, a Filovirus, an arenavirus, a hantavirus, a flavivirus, dengue virus, yellow fever virus or HIV-1.
17. The method of claim 15 , wherein the NETosis or NET formation is stimulated by a bacterium selected from at least one of a Bacillus species, and Escherichia species, a Francisella species, a Staphylococcus species, a Streptococcus species, or a Yersinia species.
18. The method of claim 10 , wherein the pharmaceutical formulation is for oral, subcutaneous, intramuscular, or intravenous administration, or administration by inhalation.
19. The method of claim 10 , wherein the patient is human.
20. A pharmaceutical kit, comprising:
a sterile-filled vial or ampoule comprising the pharmaceutical composition according to claim 1 for injection in an amount effective to inhibit NETosis or neutrophil extracellular trap (NET) formation.
21. The pharmaceutical composition of claim 1 , wherein the substitution is an incorporation of one or more amino acids with a blocking group.